Skip to main content
Caplight Logo









Arrakis Bio

Arrakis Bio

Private
IsraelHealthcare & Life Scienceshttps://www.arrakis.bio/

Last Round

Series A

Jul 22, 2026

Est. Valuation

$140M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Arrakis Bio is a biotechnology company that develops animal-free, high-quality human collagen and gelatin for medical, aesthetic, and biomedical applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

RNA-targeted small moleculerSMdrug discoverybiotechnologyRNA therapeuticssmall molecule drugsundruggable targetsdrug discovery platformbiopharmaRNA structuremedicinal chemistryAI-augmented drug discoverycomputational biologydrug development partnership

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Arrakis Bio Comparables

Compare Arrakis Bio with similar companies based on industry and business-model similarity.

Arrakis Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Expansion Therapeutics
89%
Ribometrix
88%
xFOREST Therapeutics Co., Ltd.
86%

Arrakis Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 22, 2026
SeedJul 19, 2023

Key People

Founding team and executive leadership

Dalia Rosin

CTO And Co-founder

Founding Team

Fabian Trumper

Co-Founder CEO

Founding Team

Arrakis Bio Investors

Notable investors and investment history

Arrakis Bio investors
InvestorRounds
Global Founders CapitalSeries A
Blossom CapitalSeries A
FLORA VenturesSeed
AccelSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 22, 2026

    $30M round led by Blossom Capital.

  • Jul 19, 2023

    Seed round led by FLORA Ventures.

Arrakis Bio Filings

Explore SEC and related filing metadata, where available.

Arrakis Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Arrakis Bio's valuation, stock price, and market status.

Is Arrakis Bio a public or private company?

Arrakis Bio is a private company.

What is the current stock price of Arrakis Bio?

Arrakis Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Arrakis Bio worth (valuation)?

Valuation information for Arrakis Bio is not publicly available.

Can I buy Arrakis Bio stock?

Arrakis Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Arrakis Bio's last funding round?

Arrakis Bio's most recent funding round was Seed on July 19, 2023.

Who are the main investors in Arrakis Bio?

Key investors in Arrakis Bio include FLORA Ventures.

Will Arrakis Bio IPO soon?

No public IPO plans have been announced for Arrakis Bio.

How can I track Arrakis Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Arrakis Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersIsrael
Employee Range8
Year Founded2023
Last FundingJul 22, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?